Table 2 Immunohistochemistry results
Patients | Median percentage of TDLUs containing ALDH+ cells (range) | ||
|---|---|---|---|
Luminal ductular level | Intermediate ductular level | Basal ductular level | |
Pre-menopausal with family history of breast cancer, including patients with BRCA1 or BRCA2 mutation (n = 37) | 12 (0–62)** | 12 (0–53)** | 2 (0–18) |
Pre-menopausal with BRCA1 mutation (n = 18) | 15 (2–50)* | 15 (6–38)* | 4 (0–18) |
Pre-menopausal with BRCA2 mutation (n = 13) | 14 (0–62)* | 8 (2–53)* | 0 (0–18) |
Pre-menopausal without family history of breast cancer (n = 25) | 6 (0–29) | 6 (0–44) | 0 (0–29) |
Post-menopausal receiving HRT at the time of surgery (n = 7) | 10 (0–38)* | 8 (0–38)* | 2 (0–21) |
Post-menopausal not receiving HRT at the time of surgery (n = 24) | 4 (0–32) | 4 (0–34) | 0 (0–18) |
Nocancer, underwent mammoplasty (n = 34) | 6 (0–32) | 4 (0–44) | 0 (0–29) |